Efficacy of Vedolizumab in Patients with Antibiotic and Anti-tumor Necrosis Alpha Refractory Pouchitis
To the Editor:
Refractory pouchitis is a common cause of pouch failure, which may require surgical excision of the pouch or permanent diversion. Vedolizumab, a humanized immunoglobulin G1 monoclonal antibody to a4b7 integrin, has been shown to moderate gut lymphocyte trafficking with an efficacy in treatment of both Crohn's disease and ulcerative colitis (UC). 1, 2 Although tumor necrosis factor a inhibitors have been reported to be effective as treatment for pouchitis, 3 there are no data regarding the use of vedolizumab in refractory pouchitis and it is not labeled for this use. We report a small case series of 4 patients treated with vedolizumab for antibiotic and anti-tumor necrosis factor refractory pouchitis. Four patients were identified as having refractory pouchitis and underwent pouch endoscopy before and after 3 months of therapy with vedolizumab during the period 2015 to 2016. Patient 1, a 54-year-old man, had undergone colectomy and ileal pouch-anal anastomosis in 2000 for medically refractory UC. He suffered from ankylosing spondylitis and chronic pouchitis. He had been treated serially with antibiotics, budesonide, infliximab, methotrexate, and adalimumab in combination with hyperbaric oxygen therapy. Pouchoscopy before initiation revealed confluent ulceration with the Pouchitis Disease Activity Index (PDAI) endoscopic subscore of 4. Endoscopy 4 months after the initiation of vedolizumab therapy revealed visual improvement, with few small ulcers noted, with a PDAI endoscopic subscore of 3. He experienced improvement in clinical symptoms and has avoided surgical resection of his pouch but does require maintenance therapy budesonide. Patient 2, a 54-year-old woman, underwent colectomy and ileal pouch-anal anastomosis in 1991 for medically refractory UC. She developed recurrent stricture at the pouch inlet and afferent limb and pouchitis. Treatment included surgical stricturoplasty, followed by antibiotics, thiopurines, mesalamine, intravenous immunoglobulin therapy, fecal microbiota transplant, and adalimumab. Despite these treatments, she continued to have symptoms of diarrhea and pain. Pouch endoscopy revealed chronic pouchitis with edema and loss of vascular pattern consistent with a PDAI subscore of 5, along with cuffitis, and ulcerated strictures in the neoterminal ileum. She underwent pouchoscopy 4 months after initiating therapy with vedolizumab, which revealed improvement in pouchitis with normal appearing mucosa and PDAI endoscopic subscore of 1 but ongoing ulceration at cuff and inlet. Symptom improvement was reported for both pain and diarrhea. Patient 3, a 54-yearold woman after restorative proctocolectomy for refractory UC in 2012, had required pouch redo surgery in 2014 for severe pouch dysfunction. She suffered from diarrhea requiring intravenous hydration despite use of antibiotics, infliximab with azathioprine, and mesalamine. Her pouchoscopy revealed pouchitis and ileitis with a PDAI score of 3. Pouch endoscopy 4 months after the initiation of vedolizumab revealed improved mucosa of the pouch with PDAI score of 1. She noted improvement in symptoms of diarrhea. Patient 4 was a 53-year-old woman who had undergone total abdominal proctocolectomy and pouch construction in 2004 for UC complicated by Clostridium difficile infection. She had suffered from chronic pouchitis despite treatment with antibiotics, entocort, methotrexate, and adalimumab. Pouch endoscopy while on adalimumab revealed marked ulceration with pouchitis score of 5 ( Fig. 1A) . After 3 months of vedolizumab, repeat pouchoscopy revealed resolution of ulceration with score of 1 (Fig.  1B) . She noted reduction in symptoms of diarrhea, with mild symptoms of arthralgia.
In summary, we present 4 cases of patients with refractory pouchitis who after 3 months of open-label vedolizumab therapy were noted to have improved symptoms and measurable improvement in the endoscopic appearance of the pouch. We speculate that the gut-specific immune modulation mediated by vedolizumab results in these notable responses to therapy. This warrants further study to validate the use of this medication in antibiotic and anti-tumor necrosis factor a refractory pouchitis, along with better understanding of the mechanism of this form of pouch dysfunction.
